RxDoctor Payments Data

Timothy Klein, MD

Hospitalist · Memphis, TNNPI 1164520771

Payments from drug & device makers

$201in general payments, 2019–2025

Across 7 payments — averaging $28.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$81
  • E.r. Squibb & Sons, L.L.C.$50
  • AbbVie$21
  • Melinta Therapeutics, LLC$18
  • Cashflow Solutions, LLC$18
  • KCI USA, Inc.$14

What the payments were for

  • Food & beverage$201100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cvrx, Inc.1$81
E.r. Squibb & Sons, L.L.C.2$50
AbbVie1$21
Melinta Therapeutics, LLC1$18
Cashflow Solutions, LLC1$18
KCI USA, Inc.1$14

How this compares

$201 in reported general payments places this provider in the 55th percentile of 349 hospitalist providers in Tennessee.

See all hospitalist providers in Tennessee

Medicare billing

Part B allowed, 2024
$164,766
Medicare patients
443
Services billed
2,169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban376$64,387
Daptomycin32$57,949
LinzessLinaclotide128$42,792
NuedextaDextromethorphan Hbr/Quinidine85$34,332
XareltoRivaroxaban79$20,500
OzempicSemaglutide19$19,382
ErtapenemErtapenem Sodium44$18,358
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$17,860
JanuviaSitagliptin Phosphate70$15,283
JardianceEmpagliflozin68$13,654
RybelsusSemaglutide11$11,028
NeuproRotigotine53$10,718
Pantoprazole Sodium750$9,426
CreonLipase/Protease/Amylase13$6,991
Cinacalcet Hcl47$6,641

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$21$49,783141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 349 hospitalist providers in Tennessee.

Other hospitalist in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →